Full-Time

Account Executive

Cardiopulmonary, New England

Deadline 12/12/26
LivaNova

LivaNova

1,001-5,000 employees

Global cardiopulmonary and neuromodulation devices

Compensation Overview

$75k - $85k/yr

+ Commission + Employee Stock Purchase Plan + 401(k) match

Remote in USA + 3 more

More locations: Boston, MA, USA | Providence, RI, USA | Portsmouth, NH, USA

Hybrid

Must live within the territory; 5–10% overnight travel is expected.

Bachelor's

Category
Sales & Account Management (1)
Required Skills
Sales

Get referred to LivaNova

See people who can refer or advise you

Requirements
  • At least 3 years of sales experience in the medical device industry, preferably in cardiac surgery sales, or clinical experience in cardiovascular areas such as perfusion, cardiac surgery, cardiac catheterization laboratory, or cardiovascular intensive care/critical care.
  • Demonstrated experience providing technical or clinical support to cardiac surgeons, cardiologists, or other surgical specialties in a hospital setting.
  • A Bachelor’s degree and/or clinical certification such as Certified Clinical Perfusionist, Registered Nurse, or Respiratory Therapist is required.
  • Must live within the territory.
  • Must be able to travel, including overnight travel, approximately 5–10% of the time.
  • Ability to build trusting, long-term relationships with perfusionists, cardiovascular surgeons, surgical nurses, and hospital administrators.
  • Ability to learn and sell cardiopulmonary medical devices and provide related customer support.
Responsibilities
  • Meet or exceed sales goals while maintaining appropriate sales prices, and track and analyze progress.
  • Prioritize territory accounts, assess opportunities, develop new business, and prepare weekly, monthly, and annual territory business plans.
  • Maintain account and customer profiles and account plans; develop a consultative role to manage customer training needs, build relationships, and provide customer service.
  • Support large, strategic accounts as part of a field team and work with regional and national accounts.
  • Follow company policies, communicate with corporate and field personnel, complete account and territory updates and expense and mileage submissions, and maintain hospital access and credentialing.
  • Coordinate, direct, and deliver customer training for assigned LivaNova products, including cardiopulmonary bypass disposables, heart-lung-machine equipment, and autotransfusion capital equipment and disposables.
  • Maintain frequent contact with customers in the assigned territory.
Desired Qualifications
  • Cardiac surgery sales experience.
  • Clinical experience in cardiovascular fields such as perfusion, cardiac surgery, cardiac catheterization laboratory, or cardiovascular intensive care/critical care.

LivaNova focuses on cardiopulmonary and neuromodulation medical technologies, delivering devices and therapies for heart and brain conditions. Its products, used in hospitals worldwide, include implants and related treatments that aim to improve patient health while providing clinical and economic value to healthcare systems. The company differentiates itself with a diverse, integrated portfolio backed by decades of experience and a global reach, aligning clinical outcomes with economic impact. Its goal is to improve patients’ lives by delivering meaningful health benefits and helping providers achieve better value.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

2015

Get referred to LivaNova

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 organic revenue grew 10%, with cardiopulmonary and neuromodulation both strengthening.
  • PolySync raised OSA responder rate to 84.5%, improving commercial differentiation after OSPREY.
  • FDA approval in March 2026 and next-generation submission plans expand LivaNova’s OSA franchise.

What critics are saying

  • LivaNova faces a €337.8 million SNIA liability, with hearing scheduled December 9, 2026.
  • Third-party component shortages still constrain Essenz output, limiting cardiopulmonary upside into 2026.
  • Inspire and ResMed pressure OSA adoption; aura6000 commercialization must convert approvals fast.

What makes LivaNova unique

  • LivaNova’s aura6000 is the first U.S. HGNS without CCC warning language, March 2026.
  • Essenz Perfusion System sells data-driven CPB workflows, with China launched in August 2025.
  • CORE-VNS delivered 36-month seizure reductions, reinforcing durable epilepsy credibility versus one-quarter studies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Employee Stock Purchase Plan

Flexible Work Hours

Paid Vacation

Company News

Yahoo Finance
Sep 11th, 2026
LivaNova director sells 17% of stake for $131,500

LivaNova director Francesco Bianchi sold 1,650 ordinary shares for $131,500 on 31 August 2026, according to an SEC Form 4 filing. The shares were sold at $79.72 each, whilst the stock closed at $80.16 the following day. The sale represented 17% of Bianchi's directly held shares prior to the transaction. Following the disposition, the director now holds 7,934 shares directly. LivaNova develops therapeutic medical devices across three segments: Cardiopulmonary products including oxygenators and heart-lung machines, Neuromodulation devices such as the VNS Therapy System, and Advanced Therapies solutions. The company has a market capitalisation of $4.3 billion and generated $1.5 billion in revenue over the trailing twelve months.

Business Wire
Jun 16th, 2026
LivaNova's PolySync programming achieves 84.5% response rate in obstructive sleep apnoea study

LivaNova has announced that its PolySync programming algorithm achieved an 84.5% cumulative response rate in patients with moderate to severe obstructive sleep apnea treated with proximal hypoglossal nerve stimulation. The findings were presented at SLEEP 2026 by lead author Alan Schwartz. The results build on LivaNova's OSPREY trial, which reported a 65% responder rate after 12 months. In the PolySync substudy, patients who initially did not respond underwent reprogramming using simultaneous-contact stimulation, converting most into responders and significantly improving outcomes. The approach was well tolerated with no serious adverse events. PolySync will be available with LivaNova's commercial product. The company is preparing its next-generation obstructive sleep apnea device for FDA submission in the second half of 2026, featuring MRI compatibility and rechargeable battery technology.

Business Wire
Jun 11th, 2026
Jette Nygaard-Andersen joins LivaNova board as medtech company reshuffles directors

LivaNova, a medical technology company, has appointed Jette Nygaard-Andersen to its Board of Directors following its Annual General Meeting on 10 June. Nygaard-Andersen currently chairs Coloplast A/S, a Danish medical device company, and previously served as CEO of Entain plc and in senior roles at Modern Times Group AB. The appointment coincides with Dr Sharon O'Kane stepping down after 10 years on the board. Brooke Story will succeed O'Kane as Chair of the Nominating and Corporate Governance Committee, whilst Peter Wilver assumes leadership of the Compensation and Human Capital Management Committee. LivaNova develops medical solutions for neurological and cardiac conditions, employs approximately 3,300 people, and operates in over 100 countries.

Yahoo Finance
May 6th, 2026
LivaNova posts 10% organic growth in Q2 driven by cardiopulmonary momentum and neuromodulation gains

LivaNova reported 10% organic revenue growth in Q2 2025, driven by cardiopulmonary business momentum and solid neuromodulation performance across all regions. The company also delivered operating margin expansion and strong cash generation. The company announced key clinical milestones, including long-term results from the CORE-VNS study showing an 80% median seizure reduction at 36 months for focal onset seizures and 95% for focal to bilateral tonic-clonic seizures in drug-resistant epilepsy patients. LivaNova initiated the process with CMS to seek national Medicare coverage for VNS therapy in treatment-resistant depression patients, supported by five peer-reviewed publications from the RECOVER study. The company's obstructive sleep apnea programme remains in FDA review, with management expressing confidence in its proximal hypoglossal nerve stimulation technology.

Yahoo Finance
May 6th, 2026
LivaNova posts 13% organic revenue growth in Q3, driven by cardiopulmonary surge and epilepsy gains

LivaNova reported 13% organic revenue growth in Q3 2025, driven by strong performance in cardiopulmonary and epilepsy businesses. The cardiopulmonary segment generated $203 million in revenue, up 16% year-over-year, with heart-lung machine revenue growing over 20%. The company saw accelerated placements of its Essenz heart-lung machines, with most installations in developed markets. LivaNova launched Essenz in China, its second-largest market, in August, with positive early feedback. However, expansion remains constrained by third-party component supply despite progressing manufacturing capacity plans. LivaNova unveiled a refreshed brand identity and new strategic framework, which will be detailed at its investor day on 12 November. The company is focusing on near-term performance whilst investing in core businesses and developing programmes for obstructive sleep apnoea.